<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01633554</url>
  </required_header>
  <id_info>
    <org_study_id>24190708</org_study_id>
    <secondary_id>IKalkan24190708</secondary_id>
    <nct_id>NCT01633554</nct_id>
  </id_info>
  <brief_title>ST-2; a Non-invasive Fibrosis Marker for Chronic Hepatitis B</brief_title>
  <official_title>The Ability of Prediction of Fibrosis for ST-2 as a Non-invasive Marker in Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turkiye Yuksek Ihtisas Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turkiye Yuksek Ihtisas Education and Research Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IL-33 is a recently identified number of the IL-1 family. Hepatic over-expression of IL-33
      has been recently linked to liver fibrosis. ST-2 exerts pro-inflammatory effects of IL-33. We
      aimed to determine ability of ST2 to predict fibrosis in chronic hepatitis B.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ST-2 is an IL-1 receptor family member and exists in both a membrane-bound isoform and a
      soluble (sST2) isoform. It has a functional ligand (Interleukin-33) and via ST-2/IL-33
      inflammation and immunity is regulated. Hepatic over-expression of IL-33 has been recently
      linked to liver fibrosis. ST-2 exerts pro-inflammatory effects of IL-33. We aimed to
      determine ability of ST2 to predict fibrosis in chronic hepatitis B.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Sequela of Chronic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Chronic Hepatitis B Group</arm_group_label>
    <description>Patients with chronic hepatitis B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cirrhosis</arm_group_label>
    <description>Patients with liver cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Control Group: Healthy Volunteers</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        25 Healthy Volunteers 45 patients with chronic hepatitis B 25 patients with liver cirrhosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of chronic hepatitis B or liver cirrhosis

        Exclusion Criteria:

          -  Accompanying chronic inflammatory disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>İsmail H KALKAN, MD</last_name>
    <phone>+90 312 437 67 78</phone>
    <email>drismailster@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Türkiye Yüksek İhtisas Education and research Hospital</name>
      <address>
        <city>Altındağ</city>
        <state>Ankara</state>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>İsmail H KALKAN, MD</last_name>
      <phone>+90 312 437 67 78</phone>
      <email>drismailster@gmail.com</email>
    </contact>
    <investigator>
      <last_name>İsmail H KALKAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2012</study_first_submitted>
  <study_first_submitted_qc>July 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2012</study_first_posted>
  <last_update_submitted>July 3, 2012</last_update_submitted>
  <last_update_submitted_qc>July 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turkiye Yuksek Ihtisas Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>İsmail Hakkı KALKAN</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>ST-2, IL-33, prediction, fibrosis, hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

